Picture [iito] No Tracking 650x80px
Document › Details

AstraZeneca plc. (12/20/12). "Press Release: AstraZeneca and LegoChem Biosciences Announce Collaboration on Treatment of Antibiotic-resistant Bacterial Infections".

Organisations Organisation AstraZeneca (Group)
  Organisation 2 LegoChem Biosciences, Inc. (KOSDAQ: 141080)
Products Product beta-lactam antibiotic
  Product 2 cefalosporin

AstraZeneca has entered into a research and development option & license agreement with LegoChem Biosciences to develop a novel antibiotic to treat drug-resistant bacterial infections. The treatment will potentially combine compounds from AstraZeneca's preclinical beta lactamase inhibitor (BLI) and LegoChem's preclinical cephalosporin antibiotic programs to help break down bacteria's resistance to cephalosporins.

Despite the steady rise of bacteria that are resistant to the most commonly prescribed antibiotic treatments, only two new classes of antibiotics have been introduced to the market in the past 30 years. As a result, infections caused by drug-resistant bacteria may result in prolonged illness, increased mortality risk and spread of the drug-resistant bacteria.

Cephalosporins are a class of antibiotics used in the treatment of various bacterial infections, including pneumonia, Staphylococcus aureus, and Salmonella. Investigational cephalosporin antibiotics by LegoChem Biosciences are being examined to treat Gram-negative bacteria that do not respond to current treatments, including Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumonia. Approximately 70 percent of these superbugs are resistant to antibiotics.Combining a cephalosporin with a BLI may break down the superbugs' resistance to the treatment.

"Antibiotic resistance is an urgent and growing challenge. AstraZeneca has long recognized that the discovery of successful new solutions will require collaboration and knowledge-sharing. Our collaboration with LegoChem leverages our combined expertise in antibiotics and our ability to develop innovative medicines to advance much needed treatments for antibiotic-resistant bacterial infections," said Manos Perros, head of the AstraZeneca Infection Innovative Medicines Unit.

Yong Zu Kim, LegoChem's Chief Executive Officer, said: "We are excited about this opportunity to develop our cephalosporin antibiotic with AstraZeneca's BLI program. We are impressed with the commitment of AstraZeneca's team and confident with their expertise in the anti-infective field for the successful collaboration in the development of this combination therapy." He added, "My wish is also for this partnership to fuel the continuous advancement of Korean drug discovery initiatives." LegoChem's cephalosporin project had previously received a national project grant from the Bio & Medical Technology Development Program of the Korean Ministry of Education, Science and Technology. LegoChem was counseled by Timothy H.S. Min, a Principal Attorney from SIMI Law Group of Boston, MA.

Under the terms of the agreement, each company will develop its single agent program through Phase I under the guidance of a joint research committee, and AstraZeneca will develop investigational combinations of compounds through Phase I during the option phase. AstraZeneca will be solely responsible for the development and commercialization of the candidate combination compound through the option phase, and thereafter if the option is exercised by AstraZeneca. Under the terms of the collaboration, LegoChem is eligible to receive $2.45M in initial and preclinical milestones; $20M in development milestones and $116.5M in launch and commercial milestones, as well as tiered royalties.

- ENDS -


AstraZeneca - Infection

The steady rise of drug-resistant bacteria is an imminent and urgent threat to public health. Diseases such as tuberculosis are a huge problem in the developing world and a re-emerging one in many developed countries. As one of the leading companies still actively investing in novel antibiotic research, AstraZeneca remains steadfast in our commitment to finding a solution to these crises. With one of the world's largest antibacterial pipelines and strong partnerships, we focus on the development of treatments for serious bacterial infections, viral infections and diseases of the developing world as well as diagnostics and the development of novel vaccines. For more information, visit

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit:

About LegoChem Biosciences

LegoChem Biosicences, Inc., established in May 2006 at Daedeok Innopolis, utilizes its unique LegoChemistry synthesis platform to develop novel antibiotic, anticoagulant, and anticancer drugs. They have also recently developed a novel antibody drug conjugate (ADC) platform technology to bring novel tools to solve targeted drug delivery system problems. In 1991, Dr. Yong Zu Kim developed a novel cephalosporin antibiotic that became Korea's first novel drug to be licensed out (to Glaxo Wellcome, now GlaxoSmithKline) while he was head of the research unit at LG Life Science. Dr. Kim is a leading antibiotic expert who played a major role in Korea's first FDA-approved drug "FACTIVE", also while he was at LG Life Science.

In December of 2012, LegoChem successfully met the listing requirements of the Technology Assessment Exemption Program of the KOSDAQ, and is currently in the process of becoming a publicly traded company by early 2013. For more information, please visit:


Laura Woodin
+1 302 885 1087

LegoChem Biosciences, Inc.:
Sejin Park
+042 861 0688

SIMI Law Group, P.C.:
Timothy H.S. Min
+1 617 383 4433

Record changed: 2019-06-09


Picture [iito] Plain Stupid Simple 650x80px

More documents for AstraZeneca (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81

» top